Followers | 145 |
Posts | 6539 |
Boards Moderated | 0 |
Alias Born | 03/13/2014 |
Friday, November 15, 2019 7:59:57 AM
(Alliance News) - Motif Bio PLC said Monday it agreed to settle all obligations with its former clinical research organisation without requiring any further payments.
For the six months ended June, Motif had recognised an additional USD2.4 million expense to settle this dispute. This recognition will be reversed following the agreement.
Shares in Motif Bio were 8.3% lower at 0.43 pence in London on Monday.
In October, Motif Bio announced a major restructure which would see its sell its main listeria-fighting drug iclaprim. This followed US regulators requiring iclaprim to pass further hurdles to secure new drug application status.
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM